Slingshot members are tracking this event:

Phase 1b COSMIC-021 Trial data of Exelixis'(EXEL) Cabozantinib + atezolizumab (TECENTRIQ) in Solid tumors to be presented February 13, 2020 at ASCO GU

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
EXEL Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabozantinib, Atezolizumab, Tecentriq, Solid Tumors